INTRODUCTION
The prevalence of lifetime substance use among men who have sex with men (MSM) is substantially higher than that for heterosexual men or women 1, 2 .
["MSM" is used as a narrow term that describes sexual behavior while "gay or bisexual" reflects the adoption of a sexual identity and a culture shared by MSM that extends beyond sexual behaviors.] Methamphetamine use is prevalent among MSM living in the United States 1, 3 , Australia and Western Europe 4 .
There are expressions of concern that this drug in particular may lead to accelerating new HIV infections 5 and to potential for promoting transmission of multi-drug resistant HIV 5, 6 . Among MSM, methamphetamine is frequently used alone 7 and in combination with other club drugs 8, 9 (i.e., methamphetamine, amphetamine, ecstasy, cocaine, GHB, and ketamine). With its rise in popularity in communities of gay and bisexual men, evidence has accumulated to detail not only its epidemiology, but also to describe cultural factors that facilitate its use and to indicate important ways in which methamphetamine is combined with sexual transmission behaviors.
Evidence also is accumulating on interventions that should be considered when articulating a comprehensive approach to address the high rates of methamphetamine use in MSM. This manuscript reviews the recent evidence on the epidemiology, linkages between methamphetamine use and HIV-related sexual transmission behaviors, and evidence-based interventions with methamphetamine-using MSM.
Epidemiology of Methamphetamine Use:
Around the world, 35 million people use amphetamine type stimulants (includes methamphetamine and ecstasy -MDMA), which eclipses use of all other illicit drugs excepting cannabis 10 . Reports using probability sampling in the U.S.
indicate that up to 13% of adult MSM used methamphetamine in the previous 6 months 2 . Among MSM aged [15] [16] [17] [18] [19] [20] [21] [22] 20 .1% admitted using methamphetamine 11 over a similar period.
Important questions arise regarding factors that may explain the high prevalence of methamphetamine use in MSM. One of the first qualitative studies on methamphetamine use in MSM described three shared identities relative to the drug: gay identity (the importance of methamphetamine use to facilitate gay sexual experiences and to access gay culture), crystal user identity (the perception of one's own use of methamphetamine in comparison to that of other gay or bisexual methamphetamine users) and identity regarding HIV (the ways in which methamphetamine assuages thoughts about HIV-related issues for both infected and uninfected men). 12 Qualitative reports are consistent in describing ways in which crystal methamphetamine is reported to facilitate uninhibited sexual behaviors, while ecstasy (MDMA) is reported to enhance feelings of euphoria and group connectedness 13 . Stimulant-using Latino gay men also report using methamphetamine for sexual reasons while cocaine enhances social connections 14 .
In contrast, heterosexual males and females seeking treatment of methamphetamine abuse who indicate methamphetamine is used to get high, to have fun, to get energy, to use with friends, to stay awake, to "escape," to enhance sex, to lose weight and to work more. 15 As well as informing the process of tailoring interventions that aim to reduce methamphetamine use in MSM, cultural factors unique to gay and bisexual methamphetamine users highlight how feelings of stigma and negative personal attributions, internalized or otherwise, are experienced by this group of drug users 16 .
Methamphetamine Use and Risk Behaviors for Sexually Transmitted Infections in MSM:
Physiological and psychological properties of methamphetamine make it efficient for facilitating behaviors that transmit HIV and other infectious diseases. The drug is inexpensive (approximately $25-40 U.S. per gram) and has a long half-life (8-12 hours) that enables long sexual episodes. The drug induces euphoria, brightens mood, eliminates fatigue, decreases appetite (leading to weight loss), focuses attention and for many, heightens libido 17 . MSM who use methamphetamine engage in high rates of HIV-related sexual risk behaviors. 18 In young MSM, substances are frequently combined with sex: 42.8% reported being under the influence of alcohol when having sex, 28.2% used marijuana, 9.2% used amphetamines, 8.7% used cocaine and 8.0% used amyl nitrite during sex in the previous 6 months While methamphetamine use appears associated with high-risk sexual behaviors in MSM, it is difficult to specify direct effects of the drug on HIV transmission. Methamphetamine dries the mucosa and reduces the sensitivity of the rectal and genital areas. This can facilitate longer and rougher sexual episodes and contribute to increased likelihood of bruising and tearing in the region and of increasing opportunities for transmission of infectious disease. Use of amyl nitrites and other drugs that can facilitate sexual functioning can also increase risks for disease transmission 22, 23 . Chronic use of methamphetamine can cause some men to experience erectile dysfunction, although sildenafil, vardenafil or tadalafil are used to counter this effect. The combination of sildenafil (and perhaps related compounds of vardenafil and tadalafil) with amyl nitrite in the presence of recreational use of methamphetamine and other club drugs has been reported to cause death 24 .
HIV/AIDS surveillance in the United States shows MSM to be the only behavioral risk group with increasing incidence. 25 Estimates of HIV incidence in MSM averages 1.55 per 100 persons per year (95% CI = 1.23-1.95) 23 , which corresponds to a prevalence of 19.1% in California (95% CI=12.8% to 25.3%) 26 . Incidence rates are doubled 23 or tripled 27 for MSM who use amphetamines compared to non drug-using MSM. These findings, though localized to the epidemic in the United States, indicate that methamphetamine has profound effects on decisionmaking about sexual behaviors that increase risks for disease transmission in this already at-risk group.
Methamphetamine use is also associated with transmission of other infectious diseases in MSM. In one recent report of 1,318 gay and bisexual men at a public health department clinic, 4.0% tested positive for early syphilis 28 . Factors that associated significantly with syphilis infection included being of nonwhite race, being HIV infected, using methamphetamine with sildenafil, using methamphetamine alone, using sildenafil without methamphetamine, stronger Guidelines advise initiation of a 2-or 3-drug antiretroviral therapy immediately after an exposure event (within 36-72 hours) to reduce the probability of HIV seroconversion 31 . In a Brazilian report, 200 MSM received 4 days of antiretroviral medications to take home with instructions to begin the medication immediately following a potential exposure event followed by 24 days of additional medication. Over approximately 24 months, nPEP was started by 68 MSM following 109 risk events. A total of 11 seroconversions were reported; 10 among MSM who did not use nPEP and one among those who did, a non-statistically significant difference 32 . Reasons for not using nPEP included having sex with a steady partner and not considering the risk event sufficiently high risk to start nPEP, a key problem with nPEP 33 . In high-risk groups of MSM such as methamphetamine users, clinical benefits to biomedical HIV prevention using nPEP may be of sufficient level to balance side effects and costs from the approach. Moreover, nPEP provides an optimal point for screening for sexually transmitted infections additional to HIV for MSM who seek nPEP. More intensive behavioral therapies are conducted out of drug abuse treatment clinics and involve at least weekly visits. In the largest randomized trial, cognitive behavioral therapy (Matrix Model) was compared with treatment as usual (TAU) in eight sites and 978 participants 36 . Participants assigned to Matrix Model, which uses group sessions to teach skills for instilling abstinence from methamphetamine, for avoiding relapse and for resuming abstinence should relapse occur, were 38% more likely to stay in treatment and were 31% more likely to provide a methamphetamine-metabolite free urine sample during treatment than participants receiving TAU. Treatment greatly reduced drug use in both conditions from an average of 11 of the previous 30 days at baseline to slightly over 4 days at 6-month follow-up visits.
Evidence has also accumulated for the use of contingency management (CM; i.e., providing vouchers of increasing value for successive urine samples documenting stimulant abstinence) for treatment of methamphetamine dependence. In a trial of 171 predominantly heterosexual stimulant dependent individuals randomly assigned to a CBT condition (Matrix Model), a CM condition, or a CBT+CM condition, results comparing the metabolite-free urine samples produced per condition over a 12-week study period featuring thrice weekly urine collection showed the CM condition (mean=27.6) and the CBT+CM condition (mean=28.6) to significantly outperform the CBT condition (mean=15.5). Reductions in self-reported drug use, however, were similar for all three conditions, with those at baseline averaging between 9 to 10 days of use for the previous 30 days and those at one-year follow-up visits averaging between 2 to 5 days of use.
These efficacious drug abuse treatments for heterosexual methamphetamine abusers appear to work similarly with MSM. In one controlled trial, 
